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Abstract 
Background: Recreational drug use and associated harms continue to be of significant 
concern in men who have sex with men (MSM particularly in the context of HIV and STI 
transmission. 
Methods: Data from 1484 HIV-negative MSM included in the AURAH study, a cross-
sectional, self-completed questionnaire study of 2630 individuals from 20 sexual health 
clinics in the United Kingdom in 2013-2014, was analysed. Two measures of recreational 
drug use in the previous three months were defined; (i) polydrug use(use of 3 or more 
recreational drugs)and (ii) chemsex drug use (use of mephedrone, crystal 
methamphetamine or GHB/GBL), Associations  of socio-demographic,health and lifestyle 
factors wth drug use, and associations of drug use with  sexual behaviour, were 
investigated. 
Results: Of the 1484 MSM, 350 (23.6%) reported polydrug use and 324 (21.8%) reported 
chemsex drug use in the past three months. Overall 852(57.5%) men reported condomless 
sex in the past three months; 430(29.0%) had CLS with ≥2 partners, 474(31.9%) had CLS 
with unknown/HIV+ partner(s); 187(12.6%) had receptive CLS with an unknown status 
partner. For polydrug use, prevalence ratios (95% confidence interval) for association with 
CLS measures, adjusted for socio-demographic factors were: 1.38 (1.26,1.51) for any CLS; 
2.11 (1.80, 2.47) for CLS with ≥2 partners; 1.89 (1.63,2.19) for CLS with unknown/HIV+ 
partner(s); 1.36 (1.00,1.83) for receptive CLS with an unknown status partner. 
Corresponding adjusted prevalence ratios for chemsex drug use were: 1.38 (1.26,1.52); 2.07 
(1.76,2.43); 1.88(1.62,2.19); 1.49 (1.10,2.02). Polydrug and chemsex drug use were also 
strongly associated with previous STI, PEP use, group sex and high number of new sexual 
partners. Associations remained with little attenuation after further adjustment for depressive 
symptoms and alcohol intake. 
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Conclusion: There was a high prevalence of polydrug use and chemsex drug use among 
HIV negative MSM attending UK sexual health clinics. Drug use was strongly associated 
with sexual behaviours linked to risk of acquisition of STIs and HIV.  
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Introduction 
Gay, bisexual, and other men who have sex with men (MSM) continue to be one of the 
highest risk groups for HIV in the UK and globally (Beyrer, 2012; Sullivan, 2012; Beyrer, 
2012), and experience a significant burden of ill health and harm through the use of alcohol, 
recreational drugs and tobacco (PHE, 2015). Recreational drug use in MSM and the 
associations with sexual-risk behaviour has been documented on an international level 
(Heiligenberg , 2012; Prestage, 2009, Pappas, 2011, Santos, 2013; Colfax, 2006; De Ryck, 
2013; Drumright, 2007; McCarty-Caplan, 2014) and is an important public health 
consideration in Western Europe (EMIS, 2010), particularly the UK (Kirby, 2013; Hickson, 
2010; Hunter, 2014; Daskalopoulou , 2014; Bolding, 2006; Home Office, 2013/14), where 
transmission of HIV and other sexually transmitted infections (STIs), remain high (Public 
Health England, 2014a). A 2014 report described the use of psychoactive drugs in sexual 
settings among MSM in London (Bourne, 2014). This has been termed ‘chemsex’ which 
relates to the use of certain sexually-disinhibiting recreational drugs used before or during 
sex with the specific purpose of facilitating or enhancing sex; namely any combination of 
crystal methamphetamine, mephedrone and gammahydroxybutrate / gammabutyrolactone 
(GHB/GBL) (Bourne, 2014; McCall, 2015; Bourne (a), 2015, Melendez-Torres GJ (a), 2016).  
By definition, chemsex differs from generic illicit/recreational drug use (Bourne, 2014); it is 
thought to be associated with higher-risk sexual activity, and linked to an increase in 
transmission of STIs (Stuart, 2015, Melendez-Torres GJ (b), 2016). 
Changing trends in the popularity of certain recreational drugs and combinations of poly drug 
use in MSM have been reported (Daskalopoulou, 2014, Stuart, 2013, Melendez-Torres GJ 
(a), 2016) and there is evidence that specific drugs, are associated with facilitation of HIV 
(Macdonald , 2007; Plankey, 2007; Buchacz, 2005) and STI (Hirshfield, 2004) transmission, 
increased sexual risk behaviour (Hoenigl, 2016; Mansergh, 2006), or serious overdose and 
death (Caldicott, 2004;  Liechti, 2004, ). However, there is less information relating 
specifically to HIV negative or undiagnosed MSM and recreational drug use in the UK, 
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particularly around chemsex drug use (Public Health England, 2014a) and the associations 
with sexual behaviours which are linked to risk of acquiring HIV or other STIs.  Information 
on prevalence of recreational drug use and potential associations with sexual risk behaviour 
is essential if targeted sexual health and HIV prevention policies are to be developed and 
delivered effectively to those that may benefit from them most.   
The aim of this study was to use data from a cross-sectional multi-centre study among HIV 
negative MSM attending UK GUM clinics, to assess prevalence and factors associated with 
polydrug use and chemsex drug use, and to explore the associations of drug use with sexual 
behaviour, in particular condomless sex.  
 
Methods 
AURAH (Attitudes to and Understanding of Risk of Acquisition of HIV) is a cross-sectional, 
clinic-based study that recruited HIV negative or undiagnosed participants from 20 GUM 
clinics across England between June 2013 and November 2014. Methodological details 
have been published elsewhere (Sewell, 2016). Participants completed a self-administered 
paper questionnaire that included items on demographics (gender, sexual orientation, age, 
ethnicity, UK birth, relationship status), socio-economic factors (education, employment, 
housing, money for basic needs), health and lifestyle factors (alcohol use, ascertained by a 
modified version of the WHO (AUDIT) questionnaire (Babor et al 2001), symptoms of 
depression ascertained using the Patient Health Questionnaire (PHQ-9) (Kroenke et al 
2001), symptoms of anxiety ascertained using the GAD-7 (Spitzer et al 2006), ), as well as 
recent sexual behaviour, and recent recreational drug use).  
Men were classified as MSM if they met at least one of the following criteria: (i) reported 
being gay, bisexual or reported an identity that is not explicitly based on attraction to one 
sex/gender (Galupo, 2016) (ii) reported anal sex with a man in the past three months, or (iii) 
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reported having disclosed to their family, friends or workmates as being gay, bisexual and/or 
attracted to men. 
Ascertainment of recreational drug use 
All participants were asked to report whether they had used recreational drugs in the past 
three months and, if so, to select which drug or drugs from the following list of 18 options: 
acid, lysergic acid diethylamide (LSD), or magic mushrooms (all grouped as psychedelics); 
anabolic steroids; cannabis (marijuana, grass); cocaine (coke); crack; codeine; crystal meth 
(methamphetamine); ecstasy (MDMA or E); GHB (GBL or liquid ecstasy); heroin, ketamine 
(k); khat (chat); mephedrone; morphine; opium; poppers (amyl nitrites); speed 
(amphetamine); erectile dysfunction drugs (Viagra); and other (whereby participants were 
asked to specify the drug). Other drugs specified were coded to the above categories where 
appropriate (in most cases, participants specified one of the drug options under a different or 
street name). Participants were also asked whether they had injected recreational drugs in 
the past three months.  
Recreational drug use definition 
Two measures of recreational drug-use were defined: (i) poly drug use: use of three or more 
recreational drugs (from the above list of 18) in the past three months and (ii)  chemsex drug 
use: use of one or more of mephedrone, methamphetamine or GHB/GBL in the past three 
months. It should be noted that the questionnaire did not ask about drug use during sex 
specifically.  
Sexual behaviour questions 
Eight self-reported sexual behaviour measures were derived from the questionnaire.  Sex 
was defined throughout as anal sex with men, or vaginal or anal sex with women. Four 
measures of condomless (anal or vaginal) sex (CLS) in the past three months were defined: 
(i) any CLS  (ii) CLS with two or more partners, (iii) CLS with partners of an unknown or HIV 
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positive status (men who reported only one CLS partner who was HIV positive and with 
whom they ‘thought the risks were low because their partner was taking ART’, were not 
counted as fulfilling this criterion), and (iv) receptive CLS with an unknown status partner.  
The following additional measures were also investigated: (v) self-reported diagnosis with a 
bacterial STI in the past year (Gonorrhoea, Chlamydia, Syphilis, and/or Lymphogranuloma 
venereum, LGV) and (vi) post-exposure prophylaxis (PEP) use in the past year. Finally, two 
measures of partner numbers were investigated:  (vii) report of eleven or more new sexual 
partners in the past year and (viii) group sex in the past three months. It is reported in 
Genitourinary Medicine Clinic Activity Dataset (GUMCAD) data that having a bacterial STI 
and use of PEP in the previous year are associated with increased risk of HIV acquisition in 
MSM (GUMCAD 2012).   
Statistical Analysis 
To examine the associations of specific socio-demographic factors, health and lifestyle 
factors, with (i) poly drug use and (ii) chemsex drug use, we conducted univariable analyses 
using  Pearson χ2 tests and χ2 tests for trend and multivariable analysis using modified 
Poisson regression with robust error variances to produce adjusted prevalence ratios (PRs) 
(Zou, 2004) . In adjusted models, each factor was considered in a separate model and 
adjusted for age (as a continuous variables), ethnicity (white or non-white), education 
(university degree level education or not), sexual identity (gay or bisexual/other) relationship 
status (ongoing relationship or not) and study clinic region (London, South, or 
Midlands/Yorkshire and the Humber). The associations between the two measures of drug 
use and the eight sexual behaviour measures were assessed (i) unadjusted (ii) adjusted for 
age, ethnicity, education, sexual identity, relationship status and study region, and (iii) 
adjusted for the previous factors and depressive symptoms (reporting a score of 10 or 
greater on PHQ-9) and higher risk alcohol use (score of ≥6 on the first two questions of the 
WHO AUDIT-C questionnaire). Chi-squared tests were used to assess univariable 
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associations and modified Poisson regression analysis was used to produce unadjusted and 
adjusted prevalence ratios. 
An additional analysis of the association of drug use measures with sexual behaviour was 
conducted among a restricted sample of MSM who reported anal and/or vaginal sex in the 
past three months, in order to specifically compare those having condom protected sex to 
those having CLS, when investigating recent measures of recreational drug use.  
 
Results 
Sample characteristics  
In total, 2630 individuals participated in the AURAH Study; the response rate was 60%. Of 
the 1954 male participants, 1484 were defined as MSM. Table 1 shows participants 
characteristics. The majority of MSM were of white ethnicity (n= 1196, 81.6%), 1313 (88.8%)  
self-identified as gay,141 (9.5%)  as bisexual and 25 (1.7%) as other . The median age was 
31.5 years. Overall, 1112 (74.9%) participants attended a clinic in London, 276 (18.6%) 
attended a clinic in the South and 96 (6.5%) attended a clinic in the Midlands/the North of 
England. The majority of men reported having enough money to cover basic needs (n=1062 
(71.8%)), two thirds were educated to university degree level (n=990, 66.7%) and there was 
a high rate of employment (1182 (79.6%)) (Table 2).  
 
Prevalence of recreational drug use 
Of the 1484 included MSM, 812 (55.7%) reported use of one or more recreational drug(s) in 
the past three months. Overall, 300 (20.2%) men reported use of one drug, 162 (10.9%) 
reported use of two drugs, 93 (6.3%) reported use of three drugs, 64 (4.3%) reported use of 
four drugs and 193 (13.0%) reported use of five or more drugs in the past three months.  
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Overall, 350 (23.6%) men reported poly drug use and 324 (21.8%) men reported use of at 
least one chemsex rug. Only 34 (2%) men reported injecting recreational drugs in the past 
three months.  
Overall, the most commonly reported drug used was nitrites  (32.9%) (Figure 1). This was 
followed by cannabis (21.0%), cocaine (19.4%), mephedrone (19.1%), erectile dysfunction 
drugs (17.1%), MDMA  (13.0%),  GHB/GBL (12.0%), ketamine (8.4%) and 
methamphetamine  (6.4%). The other drugs had a prevalence of use of <5%. 
Correlates of recreational drug use  
Table 1 shows the association of socio-demographic,health and lifestyle factors with the two 
measures of recreational drug use, in the past three months.  
In univariable analysis, younger age, non-university education, non-home ownership, not 
being in an ongoing relationship, attending a clinic in London or the South, higher risk 
drinking, and depressive symptoms were associated with poly drug use in the past three 
months. The prevalence of poly drug use also appeared to be higher among men of white 
ethnicity, although the association was of borderline statistical significance. After adjusting 
for socio-demographic factors (age, ethnicity, sexual identity, education, relationship status 
and study clinic region), with the exception of non-home ownership, these associations with 
polydrug use remained There was also evidence of an  association between financial 
hardship and poly drug use after adjustment for socio-demographic factors. 
A similar pattern was observed for chemsex drug use, whereby, younger age, non-university 
education, not being in an ongoing relationship, attending a clinic in London or the South, 
financial hardship, higher risk drinking and depressive symptoms were  found to be  
associated with use of chemsex drugs, including after adjustment for socio-demographic 
factors. Additionally, men who identified as gay were more likely to report chemsex drug use 
in unadjusted and adjusted analysis compared to those who identified as bisexual or other. 
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Prevalence of sexual behaviour measures 
Of the 1484 MSM, over half reported having CLS within the past three months (n=853; 
57.5%), of these men, 91.7% had CLS with men only, 3.9% had CLS with both men and 
women, and 4.5% had CLS with women only (Table 1). Of the 33 men who reported CLS 
with both men and women, 18.2% (n=6) reported anal CLS with a woman at least once, and 
of the 38 men who reported CLS with women only, 31.6% (n=12) reported anal CLS at least 
once.  Furthermore, 29.0% % (n=430) of men reported CLS with ≥ 2 partners in the past 
three months, 31.9%  (n=474) of men reported CLS with unknown/HIV positive status 
partners (excluding men who reported one HIV positive long-term CLS partner with whom 
they thought the risks were low because their partner was taking ART), 12.6% (n=187) of 
men reported receptive CLS with an unknown status partner, 34.1%  (n=506) of men 
reported eleven or more new sexual partners in the past year and 35.5% (n=527) reported 
group sex in the past three months. Overall 441  MSM (29.7%) ) self-reported a bacterial STI 
diagnosis in the past year. The most common bacterial STI reported was gonorrhoea 
(21.8%, n=323) followed by chlamydia (14.0%, n=208) Fourteen percent (n=212) of all MSM 
had reported using post-exposure prophylaxis (PEP) within the previous year. Participants 
were also asked whether they had ever taken PrEP and 4.5% reported that they had. 
 
Relationship between recreational drug use and sexual behaviour  
Comparing men who reported poly drug use in the past three months with men who did not, 
there was a significantly higher prevalence in the past three months of; any CLS (71.4% vs. 
53.2%), CLS with two or more partners (47.4% vs. 23.3%), CLS with unknown/HIV positive 
status partner(s) (49.7% % vs. 26.5%), receptive CLS with an unknown status partner 
(16.0% vs. 11.6%), bacterial STI diagnosis (47.4% vs. 24.3%), PEP use (24.0% vs. 11.3%), 
report of eleven or more new sexual partners (56.3% vs. 27.3%) and group sex (66.0% vs. 
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26.1%); all χ2 p values <0.001 (with the exception of receptive CLS with an unknown status 
partner; χ2 p=0.028).  
The results were similar for chemsex use. Compared to men who did not use chemsex 
drugs, those who did had a higher prevalence of; any CLS (80.0% % vs. 53.7%), CLS with 
two or more partners (47.5% vs. 23.8%), CLS with unknown/HIV positive status partner(s) 
(50.0% % vs. 26.9% ), receptive CLS with an unknown status partner (17.0% vs. 11.4%), 
bacterial STI diagnosis (53.4% vs. 23.1%), PEP use (29.0% vs. 10.2%), report of eleven or 
more new sexual partners (57.7% vs. 27.5%) and group sex (69.8% vs. 26.0%); all p values 
<0.001 (with the exception of receptive CLS with an unknown status partner; p=0.007).  
Figures 2A, and 2B show the strong associations found between poly drug and chemsex 
drug use respectively, with the sexual behaviour outcomes. The prevalence ratios are shown 
as (i) unadjusted, (ii) adjusted for socio-demographic factors (age, ethnicity, education, 
sexual identity, relationship status, and study region) and (iii) adjusted for socio-demographic 
factors plus higher risk drinking and depressive symptoms. Poly drug use remained strongly 
associated with the sexual behaviour measures after adjustment for socio-demographic 
factors (any CLS [Prevalence Ratio 1.38 95% CI: 1.26, 1.51], CLS with ≥2 partners [PR 2.11 
95% CI: 1.80, 2.47] CLS with unknown/HIV+ partner(s) [PR 1.89 95% CI: 1.63, 2.19], 
receptive CLS with an unknown status partner [PR 1.36 95% CI: 1.00, 1.83], STI diagnosis 
[PR 1.85 95% CI: 1.58, 2.16], PEP use [PR 2.06 95% CI: 1.59, 2.67], ≥11 new sex partners 
[PR 1.99 95% CI: 1.74, 2.28], and group sex [PR 2.59 95% CI: 2.29, 2.94]). After adjusting 
additionally for higher risk drinking and depressive symptoms, most associations were 
slightly attenuated but remained significant.   
Similarly, chemsex drug use remained strongly associated with the sexual behaviour 
measures after adjustment for socio-demographic factors (any CLS [Prevalence Ratio 1.38 
95% CI: 1.26, 1.52], CLS with ≥2 partners [PR 2.07 95% CI: 1.76, 2.43] CLS with 
unknown/HIV+ partner(s) [PR 1.88 95% CI: 1.62, 2.19], receptive CLS with an unknown 
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status partner [PR 1.49 95% CI: 1.10, 2.02], STI diagnosis [PR 2.22 95% CI: 1.91, 2.58], 
PEP use [PR 2.78 95% CI: 2.16, 3.58], ≥11 new sex partners [PR 1.94 95% CI: 1.69, 2.22], 
and group sex [PR 2.73 95% CI: 2.41, 3.09]). Again, adjusting additionally for higher risk 
drinking and depressive symptoms, most associations were slightly attenuated but remained 
significant.   
The associations of polydrug use and chemsex drug use with the sexual behaviour 
measures remained strong for most of the sexual behaviour measures in the subgroup of 
1340 MSM who had anal or vaginal sex in the past three months, as shown in Table 3,  
 
Discussion 
Our results demonstrate that over half (55.7%) of the HIV negative MSM attending sexual 
health services during the study period (2013-14) had reported use of one or more 
recreational drugs in the past three months. Nearly a quarter (23.6%) of these men reported 
use of three or more drugs, and over a fifth (21.8%) reported use of at least one chemsex 
drug (though use of chemsex drugs does not necessarily equate to engaging in chemsex). 
There was a striking association between the two measures of recreational drug use and 
measures of CLS, these associations were only slightly attenuated when adjusted for socio-
demographic factors (age, ethnicity, education, sexual identity, relationship status, study 
region), and most remained after additional adjustment for alcohol use and symptoms of 
depression.  
The prevalence of recreational drug use in our clinic-based study is higher than that found by 
the third National Survey of Sexual Attitudes and Lifestyles (NATSAL-3) which included a 
small sample of MSM recruited from a general population study (n=190) (Mercer et all 2016), 
and demonstrated that 36% of all MSM had reported any recreational drug use in the past 
year. Our estimated prevalence of recreational drug use is also higher than that reported by 
the Crime Survey for England and Wales (CSEW) 2013/2014 (Home Office, 2013/14) which 
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demonstrated that gay or bisexual men were the group most likely to have taken any illicit 
drug in the past year (33.0%). Differences in sampling frame (recruited through STI clinics) 
and the younger average age of the AURAH participants may account for the higher 
prevalence of recreational drug use in the AURAH study. 
In AURAH, the most commonly used recreational drug was nitrites  (since made illegal by 
the Psychoactive Substance Act 2016 (Santos, 2014)), which have been shown to be 
associated with increased risk of HIV transmission (Romanelli et al 2004). Overall 32.9% of 
MSM reported use of nitrites within the past three months. This is similar to the UK 
prevalence of nitrite use in the past month (29%) found in the European MSM Internet Sex 
Survey (EMIS), a European-wide (38 countries) volunteer online sample of MSM in 2010, in 
which the UK had the second highest prevalence of nitrite use (the overall prevalence was 
19% and 28.3% in the Western Europe sub-region) (EMIS, 2010). EMIS also presented the 
prevalence of other drug composites in the past month, in the Western Europe sub-region 
(Belgium, France, Netherlands, United Kingdom, and Republic of Ireland) these included; 
cannabis or LSD at 13.8%, heroin or crack at 0.4% and ‘party drugs’ (MDMA, 
amphetamines, methamphetamine, mephedrone, GHB/GBL, ketamine or cocaine) at 10.6% 
(17% in the UK) (EMIS, 2010). For the equivalent composite measures in AURAH, the 
prevalence was the same at 0.4% for heroin or crack use in the past three months and 
higher at 33.1% for ‘party drug’ use in the past three months. The higher prevalence for the 
latter measure may not be surprising given the differences in recall periods of drug use 
between the studies. In the AURAH study, men were asked about LSD use as part of a 
group of other psychedelic drugs, prohibiting comparison with the cannabis/LSD measure 
investigated in EMIS. 
The Gay Men’s Sex Survey (GMSS) is an annual community-based survey for MSM that 
(since 2003) collects data from volunteer convenience samples of men using gay community 
and commercial websites (as well as snowball sampling). The most recent survey was 
carried out from July-October 2014 in England (N=15360). HIV diagnosed individuals were 
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included in the sample (9%). Data was collected on recreational drug use; in the past six 
months, 34.6% of all men reported using nitrites, 19.0% erectile dysfunction drugs, 19.9% 
cannabis, 11.5% MDMA, 3.8% amphetamine, 3.8% methamphetamine, 0.3% heroin, 4.6% 
ketamine, 1.1% psychedelics, 12.7% cocaine, 0.7% crack cocaine, 8.5% mephedrone, and 
5.2% GHB/GBL. Although the recall period for drug use in AURAH (past three months) was 
half that of the GMSS 2014, the prevalence of reported use of methamphetamine (6.4%), 
ketamine (8.4%), cocaine (19.4%), mephedrone (19.1%), and GHB/GBL (12.0%) was 
higher. For all other drugs, the prevalence was similar or slightly lower in the AURAH study. 
Again, this may be affected by age differences between the two studies (although the 
median ages were similar and the GMSS 2014 included men aged 16 years or older instead 
of 18 years or older in AURAH), the inclusion of men with diagnosed HIV (although a small 
proportion of the sample were positive), or more likely the fact that AURAH was a sample of 
GUM clinic service users, who may report different patterns of behaviour to men recruited 
online (Hickson et al 2016).  
In the current study, younger age, markers of lower socio-economic status (non-university 
degree education and financial insecurity), not being in an ongoing relationship, attending a 
study clinic in London, higher risk drinking and report of depressive symptoms, were found to 
be associated with poly drug use and chemsex drug use. There is little information from 
quantitative studies on factors associated with recreational drug use among HIV negative 
MSM in the UK. In GMSS 2014, living in London and having diagnosed HIV were found to 
be associated with chemsex drug use (methamphetamine, mephedrone and/or GHB/GBL- 
men were not asked whether drug use occurred before or during sex). Europe-wide data 
from EMIS found that younger age was associated with use of ‘party drugs’ in the past 
month (adjusted for factors including recruitment online site, education, settlement size, HIV 
status, outness, European sub-region, gay community/commercial venue attendance and 
CLS with a man) (EMIS, 2010). In AURAH, men who identified as gay were more likely to 
report chemsex drug use than men who did not, and this is in line with the findings described 
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in UK qualitative work on chemsex drug use (Bourne et al 2014; Bourne et al 2015a; Bourne 
et al 2015b).    
In general, it has been suggested that MSM’s use of recreational drugs is potentially part of 
coping with minority and other stressors (Meyer 1995; Meyer et al 2013). Worry, stigma and 
victimization associated with a sexual minority status (as described in minority stress theory) 
may lead to high levels of psychological distress (including depression, anxiety and PTSD). 
The ‘gay scene’ (including clubs, bars, pubs, saunas etc.) can represent a culturally 
endorsed ‘time-out’ from stresses common to the gay community (and other sexual minority 
men). Drug use often plays a key role in escaping self-awareness of social and sexual 
norms. For many men, the ‘scene’ is an important social nexus (Caudill & Marlatt 1975; 
Crowe & George 1989; McKirnan et al 1996; Meyer et al 2013) where gay sexuality is 
sanctioned and celebrated (Caudill & Marlatt 1975; Crowe and George 1989). 
The transmission of STIs and HIV are facilitated by, or in the case of HIV largely due to CLS. 
A modelling study suggested that for HIV, the majority of transmissions are due to CLS with 
a casual, rather than long-term, partner (Phillips, 2015). One UK study, the SALLEE study in 
2009 (online sample of 616 MSM), has presented an adjusted OR (controlling for socio-
demographic factors; age, education, nationality, language of questionnaire, time spent in 
UK, living in London and recruitment site, health and lifestyle factors; HIV status and 
injection drug use, and sexual behaviour measures; having been paid for sex in the UK) for 
the association between any recreational drug use in the past year and sexual risk 
behaviour. Men who reported drug use were found to be more likely to report CLS with a 
casual partner in the past year (AOR 2.07 95% CI: 1.40, 3.06; p<0.001), than men who did 
not. This study was restricted to MSM who self-identified as migrants from one of the ten 
Central and Eastern European Countries (Evans et al 2011). 
Of note, chemsex is a newly emerging and fast developing phenomenon in the UK. 
Qualitative work (2013-2014) among a volunteer sample of MSM (promotion via a gay social 
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networking app, and a London gay ‘scene’ publication, and referral from gay/bisexual 
charities) suggests that serosorting practices are common among HIV positive men who 
engage in chemsex (i.e. seeking CLS with partners of the same, HIV positive status, to 
themselves). At the same time, it suggests that a number of men whose last HIV test was 
negative had unintentional CLS as a direct result of ‘chem’ use (Bonell et al 2010; Bourne et 
al 2015; Bourne et al 2015). 
There is also evidence to suggest that the HIV transmission risk associated with CLS may 
be enhanced by substance use (Hirshfield, 2015; Purcell, 2005; Colfax, 2004; Melendez-
Torres (b) 2016,) that is considered syndemic among MSM (Melendez-Torres (a), 2016; 
Santos, 2014). There is evidence that some specific drugs may facilitate the biological 
mechanism of HIV transmission, these may include nitrites (Hirshfield, 2005), amphetamines 
(Hoenigl, 2016) and certain combinations of drugs (Drumright, 2006; Ostrow, 2009). 
Recreational drug use may also impact on other aspects of physical and psychological 
health and wellbeing. The use of chemsex drugs such as GHB/GBL alone and in 
combination with other drugs such as mephedrone pose a risk of serious overdose (Galicia, 
2011) and death (Aromatario, 2012), and studies have increasingly reported on the harmful 
effects of psychoactive substances in highly sexual circumstances (Bourne (b) 2015, 
Melendez-Torres GJ (b) 2016) However, in discussing the risk associated with recreational 
drug use, it is important to emphasise that some individuals may perceive positive benefits 
from drug (and alcohol) use, whether or not they experience any negative consequences. 
We did not ask in this study about individuals’ perceptions or experiences of drug use, 
whether positive or negative, though this has been explored in other studies (Weatherburn 
P, 2016; Bourne A (a) 2015). It is important that sexual health services recognise the 
motivations for gay men engaging in chemsex, often described as facilitating sexual self-
confidence or self- esteem, as well as discussing the potential harms of drug use.    
Recent advances in HIV prevention, including results from the PROUD (McCormack, 2016) 
and IPERGAY (Molina, 2015) studies, which both demonstrated the highly protective effect 
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(86%) of pre-exposure prophylaxis (PrEP) for HIV negative MSM, are highly relevant to 
MSM who report recreational drug use. As previous research has demonstrated that drug 
use among MSM is generally episodic rather than continuous (McCarty-Caplan, 2014) and, 
given the strong association between measures of recreational drug use and increased 
sexual risk behaviour among HIV negative MSM demonstrated in the AURAH study, 
identification of MSM using particular drugs associated with chemsex could help to identify 
those that are most likely to benefit from access to PrEP.  
 
Strengths and limitations 
AURAH is the largest published study of recreational drug use among HIV negative or 
undiagnosed MSM attending sexual health clinics in the UK. A limitation of the study is that 
the reporting of use of chemsex drugs does not necessarily equate to engagement in 
chemsex; for example mephedrone use may be associated with clubbing or other social 
activity. In addition, AURAH did not collect information on personality traits associated with 
sensation seeking and compulsivity, factors that have been found to be associated with 
recreational drug use (Singer & Clair 2003; Singer et al 2006; Jie et al 2012; Parsons et al 
2012). Furthermore, although potential causal mechanisms between certain drugs and 
associations with HIV/STIs have been identified (Drumright, 2006), causality cannot be 
determined in this cross-sectional study and it is recognised that both recreational drug use 
and sexual risk behaviour may be part of pre-disposition to risk (Drumright, 2006). Whatever 
the direction of association, exposure to HIV and STIs remains a serious risk among HIV 
negative MSM who use recreational drugs, and there is a need for further longitudinal and 
qualitative studies to allow us to develop better understandings of the motivations for 
recreational drug use among HIV negative MSM, and the link with sexual behaviour. 
Conclusions 
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The high prevalence of poly drug, and chemsex drug use reported by HIV negative MSM in 
the AURAH study points to a clear need for cross-agency collaboration to provide non-
judgemental, tailored services that are accessible to HIV negative MSM through sexual 
health services. Active identification of MSM at increased risk of HIV acquisition who would 
benefit from potential HIV prevention interventions is vital, and consideration should be given 
to all MSM that report recreational drug use, and particularly those that report use of multiple 
or chemsex drugs. Among MSM, particularly in London, engagement with sexual health 
services is generally high (Bourne, 2014), which places these services in an opportune 
position to offer education, screening and interventions for different types of drug use. In 
addition, identification of recreational drug use within the sexual health setting may also 
highlight the need for opportune assessment by psychology or mental health teams that may 
be of benefit to individuals. Greater consideration should be given to the impact of 
recreational drug use on HIV and STI prevention strategies and allocation of funding and 
research to allow existing services to integrate harm reduction strategies into patient care.  
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Table 1: Unadjusted and adjusted associations of socio-demographic and lifestyle factors with measures of recreational drug use 
(past 3 months) 
N=1484 MSM   Poly drug use (use of 3 or more recreational 
drugs) 
Use of least one ‘chemsex’ associated 
drug (crystal meth/meph or GHB/GBL) 
  N (%) % 
p value† 
Adjusted PR** 
[95% CI] 
Overall p value 
% 
p value† 
Adjusted PR** 
[95% CI] 
Overall p value 
Age in years <25 
25-29 
30-34 
35-39 
40-44 
45+ 
254 (17.4%) 
372 (25.4%) 
277 (18.9%) 
193 (13.2%) 
143 (9.8%) 
225 (15.4%) 
25.6% 
20.7% 
29.6% 
27.5% 
21.0% 
17.3% 
0.011 
0.126* 
1.49 [1.04, 2.13] 
1.21 [0.85, 1.72] 
1.77 [1.26, 2.49] 
1.71 [1.18, 2.47] 
1.32 [0.86, 2.01] 
1 
0.005 
0.166* 
20.9% 
18.8% 
28.9% 
25.9% 
21.7% 
16.0% 
0.005 
0.550* 
1.29 [0.88, 1.90] 
1.15 [0.80, 1.66] 
1.80 [1.27, 2.55] 
1.67 [1.14, 2.45] 
1.44 [0.94, 2.19] 
1 
0.003 
0.753 
Born in the UK and white 
ethnicity 
Yes, white 
Yes, non-white 
No, white 
No, non-white 
759 (51.8%) 
97 (6.6%) 
437 (29.8%) 
172 (11.7%) 
24.9% 
16.5% 
24.9% 
17.4% 
0.058 
1 
0.60 [0.37, 0.97] 
0.96 [0.78, 1.17] 
0.70 [0.49, 1.00] 
0.062 
22.0% 
14.4% 
23.8% 
19.2% 
0.185 
1 
0.67 [0.40, 1.14] 
1.01 [0.82, 1.26] 
0.91 [0.65, 1.27] 
0.464 
Sexual identity Gay 
Bisexual*** 
Other**** 
1313 (88.8%) 
141 (9.5%) 
25 (1.7%) 
24.1% 
19.9% 
12.0% 
0.204 
1 
0.90 [0.64, 1.27] 
0.59 [0.20, 1.73] 
0.540 
23.2% 
12.1% 
4.0% 
0.001 
1 
0.56 [0.35, 0.88] 
0.20 [0.03, 1.48] 
0.013 
Money to cover basic 
needs 
All the time 
Most of the time 
Sometimes/never 
1062 (71.8%) 
311 (21.0%) 
107 (7.2%) 
23.5% 
22.2% 
29.9% 
0.258 
0.376* 
1 
0.92 [0.72, 1.16] 
1.38 [1.02, 1.87] 
0.057 
0.287* 
21.6% 
19.9% 
30.8% 
0.056 
0.179* 
1 
0.95 [0.74, 1.22] 
1.71 [1.27, 2.30] 
0.001 
0.027* 
University education Yes 
No 
990 (66.7%) 
494 (33.3%) 
21.5% 
27.7% 
0.008 
1 
1.39 [1.15, 1.67] 
0.001 
20.5% 
24.5% 
0.080 
1 
1.34 [1.10, 1.63] 
0.004 
Employment (full or part 
time) 
Yes 
No 
1182 (79.6%) 
302 (20.4%) 
23.4% 
24.5% 
0.674 
1 
1.07 [0.85, 1.34] 
0.590 
21.8% 
21.9% 
0.992 
1 
1.04 [0.82, 1.33] 
0.742 
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Table 1: Unadjusted and adjusted associations of socio-demographic and lifestyle factors with measures of recreational drug use 
(past 3 months) (continued) 
Housing situation ‡ Home owner 
Renting 
Unstable/ 
Other 
421 (28.8%) 
832 (56.9%) 
210 (14.4%) 
 
19.0% 
25.6% 
24.3% 
0.033 
0.047* 
1 
1.16 [0.90, 1.50] 
1.15 [0.81, 1.62] 
0.517 
0.390* 
18.3% 
23.4% 
22.4% 
0.111 
0.114* 
1 
1.16 [0.89, 1.50] 
1.20 [0.84, 1.72] 
0.502 
0.284* 
Ongoing relationship 
with a partner 
Yes 
No 
640 (43.1%) 
844 (56.9%) 
18.6% 
27.4% 
<0.001 
1 
1.35 [1.11, 1.65] 
0.003 
15.9% 
26.3% 
<0.001 
1 
1.53 [1.24, 1.89] 
<0.001 
Study region London 
South 
Midlands & the North 
1112 (74.9%) 
276 (18.6%) 
96 (6.5%) 
24.6% 
23.9% 
11.5% 
0.015 
1 
0.90 [0.71, 1.14] 
0.42 [0.24, 0.73] 
0.008 
23.4% 
21.0% 
6.3% 
<0.001 
1 
0.83 [0.64, 1.08] 
0.25 [0.12, 0.55] 
0.001 
Higher risk drinking₽ Yes 
No 
288 (19.4%) 
1196 (80.6%) 
36.1% 
20.6% 
<0.001 
1.65 [1.37, 2.00] 
1 
<0.001 
31.9% 
19.4% 
<0.001 
1.58 [1.29, 1.93] 
1 
<0.001 
Current symptoms of 
depression  
(PHQ-9≥10) 
Yes 
No 
185 (12.5%) 
1299 (87.5%) 
33.0% 
22.3% 
0.001 
1.46 [1.15, 1.85] 
1 
0.002 
29.2% 
20.8% 
0.010 
1.45 [1.13, 1.87] 
1 
0.004 
Current symptoms of 
anxiety (GAD-7≥10) 
Yes 
No 
158 (10.7%) 
1326 (89.4%) 
 
26.6% 
23.2% 
0.348 
1.14 [0.86, 1.52] 
1 
0.357 
22.0% 
20.9% 
0.761 
0.99 [0.71, 1.38] 
1 
0.960 
 
†χ2 test 
*Test for trend. 
**Each factor considered in a separate model adjusted for age (as a continuous variable), ethnicity (white or non-white), sexual identity (gay or 
bisexual/other), education, ongoing relationship status and study region. 
***Includes men who identified as queer, pansexual, omnisexual, open, bi-curious, and transgendered. 
****Includes men who identified as straight/heterosexual, three of whom specified a ‘straight identity but have/had sex with a man’. 
‡Renting includes from a private landlord and council or housing association. Unstable includes temporary accommodation (hostel, shelter, bed and 
breakfast, squat), staying with partner/friend(s)/family and homeless. 
₽ Higher-risk drinking is based on the first two questions of the WHO AUDIT-C questionnaire. Higher risk drinking is indicated by a score of ≥6 and lower risk 
drinking/no alcohol consumption by a score of <6 (Babor, 2001).
  
24 
  
Table 2: Prevalence of sexual behaviours among 1484 MSM  
 All MSM [N=1484] 
 n (%)  
(95% CI) 
Any CLS (past 3 months) 853 (57.5%) 
(54.9%, 60.0%) 
CLS with two or more partners (past 3 months) 430 (29.0%) 
(26.7%, 31.3%) 
CLS with unknown/HIV positive status partner(s)* (past 3 months) 
 
474 (31.9%)  
(29.6%, 34.4%) 
Receptive CLS with an unknown status partner(s) (past 3 months) 187 (12.6%) 
(11.0%, 14.4%) 
Self-reported bacterial STI diagnosis (past year) 441 (29.7%) 
(27.4%, 32.1%) 
PEP use (past year) 212 (14.3%) 
(12.6%, 16.2%) 
Eleven or more new sexual partners (past year)  506 (34.1%) 
(31.7%, 36.6%) 
Group sex (past 3 months) 527 (35.5%) 
(33.1%, 38.0%) 
**Excludes men who reported one HIV positive long-term CLS partner with whom they 
thought the risks were low because their partner was taking ART. 
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Figure 1: Prevalence of individual recreational drug use in the past three months 
among 1484 MSM 
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Figure 2A: Association poly drug use in the past three months with sexual behaviour 
measures among 1484 MSM 
 
 
 
*Excludes men who reported one HIV positive long-term CLS partner with whom they thought the 
risks were low because their partner was taking ART. 
**The model was fitted to include continuous age and dichotomous ethnicity (white or non-white) and 
self-reported sexual identity (gay or bisexual/other). 
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Figure 2B: Association of chemsex drug use in the past three months with sexual 
behaviour measures among 1484 MSM 
 
 
 
*Excludes men who reported one HIV positive long-term CLS partner with whom they thought the 
risks were low because their partner was taking ART.  
**The model was fitted to include continuous age and dichotomous ethnicity (white or non-white) and 
self-reported sexual identity (gay or bisexual/other).
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Table 3: Unadjusted and adjusted associations of poly drug use and chemsex drug use with measures of sexual risk behaviour 
among 1340 MSM who reported having anal or vaginal sex in the past three months 
N=1340 MSM reporting 
anal/vaginal sex in the 
past three months 
Poly drug use (past three months)  Chemsex drug use (past three months) 
Sexual behaviour/risk 
outcome measure: 
Unadjusted 
PR[95% CI]   
 p value‖ 
Adjusted model 
(i) 
PR[95% CI]    
p value‖ 
Adjusted model 
(ii) 
PR[95% CI] 
p value‖ 
Unadjusted 
PR[95% CI]   
 p value‖ 
Adjusted model  
(i) 
PR[95% CI]    
p value‖ 
Adjusted model  
(ii) 
PR[95% CI] 
p value‖ 
Any CLS (past three 
months) 
1.21 [1.12, 1.32] 
<0.001 
1.26 [1.16, 1.36] 
<0.001 
1.25 [1.15, 1.35] 
<0.001 
1.21 [1.12, 1.32] 
<0.001 
1.28 [1.17, 1.39] 
<0.001 
1.27 [1.16, 1.38] 
<0.001 
CLS with two or more 
partners (past three 
months) 
1.84 [1.58, 2.14] 
<0.001 
1.90 [1.63, 2.22] 
<0.001 
1.84 [1.57, 2.15] 
<0.001 
1.83 [1.57, 2.13] 
<0.001 
1.89 [1.61, 2.21] 
<0.001 
1.82 [1.55, 2.14] 
<0.001 
CLS with unknown/HIV 
positive status partner* 
(past three months) 
1.70 [1.48, 1.96] 
<0.001 
1.70 [1.47, 1.97] 
<0.001 
1.65 [1.42, 1.91] 
<0.001 
1.70 [1.48, 1.96] 
<0.001 
1.72 [1.48, 1.99] 
<0.001 
1.67 [1.44, 1.94] 
<0.001 
Receptive CLS with 
unknown status partner 
(past three months) 
1.25 [0.94, 1.67] 
0.126 
1.22 [0.91, 1.65] 
0.184 
1.19 [0.87, 1.61] 
0.275 
1.37 [1.02, 1.82] 
0.033 
1.36 [1.01, 1.84] 
0.045 
1.33 [0.98, 1.81] 
0.070 
Bacterial STI diagnosis 
(past year) 
1.87 [1.61, 2.18] 
<0.001 
1.79 [1.53, 2.09] 
<0.001 
1.75 [1.49, 2.05] 
<0.001 
2.25 [1.94, 2.60] 
<0.001 
2.18 [1.87, 2.54] 
<0.001 
2.14 [1.83, 2.50] 
<0.001 
PEP use (past year) 2.00 [1.56, 2.57] 
<0.001 
1.93 [1.48, 2.50] 
<0.001 
1.83 [1.41, 2.39] 
<0.001 
2.73 [2.14, 3.48] 
<0.001 
2.64 [2.04, 3.40] 
<0.001 
2.53 [1.95, 3.27] 
<0.001 
Eleven or more new 
sexual partners (past 
year) 
1.98 [1.73, 2.27] 
<0.001 
1.91 [1.66, 2.18] 
<0.001 
1.87 [1.63, 2.15] 
<0.001 
2.02 [1.77, 2.31] 
<0.001 
1.86 [1.62, 2.14] 
<0.001 
1.83 [1.59, 2.10] 
<0.001 
Group sex (past three 
months) 
2.45 [2.16, 2.78] 
<0.001 
2.50 [2.20, 2.84] 
<0.001 
2.50 [2.19, 2.84] 
<0.001 
2.62 [2.31, 2.96] 
<0.001 
2.65 [2.33,3.01] 
<0.001 
2.64 [2.32, 3.01] 
<0.001 
‖ P value by Wald test. 
Adjusted model (i): Age (as a continous variable), ethnicity (white or non-white), sexual identity (gay or bisexual/other), university education, ongoing 
relationship status and study region.  
Adjusted model (ii): Age (as a continuous variables), ethnicity (white or non-white), sexual identity (gay or bisexual/other), university education, ongoing 
relationship status, study region, higher risk drinking, and depressive symptoms (PHQ-9≥10). 
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*Excludes men who reported one HIV positive long-term CLS partner with whom they thought the risks were low because their partner was taking ART. 
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